Literature DB >> 7371463

Impaired elimination of caffeine in cirrhosis.

P V Desmond, R V Patwardhan, R F Johnson, S Schenker.   

Abstract

The effect of cirrhosis on the disposition and elimination of caffeine was examined. Caffeine (250 mg) was administered orally to 15 healthy controls and eight patients with cirrhosis. The elimination half-life was prolonged from 5.2 +/- 2.4 hr (mean +/- SD) in controls to 6.1 +/- 1.9 hr in cirrhotics, although this did not reach statistical significance. The plasma clearance, however, was significantly higher (1.4 +/- 0.5 ml/min/kg) in controls as compared to cirrhotics (0.9 +/- 0.3 ml/min/kg) (P less than 0.05). The plasma binding of caffeine was also lower in cirrhotics (31.3 +/- 1.8% vs 25.5 +/- 4.0%, P less than 0.01). The plasma clearance of unbound caffeine therefore was reduced from 2.0 +/- 0.7 ml/min/kg in controls to 1.2 +/- 0.4 ml/min/kg (P less than 0.01) in cirrhotics, demonstrating impaired elimination of caffeine in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7371463     DOI: 10.1007/bf01308138

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  The fate of caffeine in man and a method for its estimation in biological material.

Authors:  J AXELROD; J REICHENTHAL
Journal:  J Pharmacol Exp Ther       Date:  1953-04       Impact factor: 4.030

3.  Letter: Caffeine accumulation associated with alcoholic liver disease.

Authors:  B E Statland; T Demas; M Danis
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

4.  Response of free fatty acids to coffee and caffeine.

Authors:  S Bellet; A Kershbaum; E M Finck
Journal:  Metabolism       Date:  1968-08       Impact factor: 8.694

Review 5.  Physiological disposition of caffeine.

Authors:  A W Burg
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

6.  Effect of smoking on caffeine clearance.

Authors:  W D Parsons; A H Neims
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

Review 7.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

8.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

9.  Effects of caffeine on plasma renin activity, catecholamines and blood pressure.

Authors:  D Robertson; J C Frölich; R K Carr; J T Watson; J W Hollifield; D G Shand; J A Oates
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

  9 in total
  18 in total

1.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

2.  Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

Authors:  H Kraul; J Truckenbrodt; A Huster; R Töpfer; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 5.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

6.  Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models.

Authors:  Dorra Ben Said; Ridha Ben Ali; Henda Ferchichi; Issam Salouage; Lobna Ouanes; Emna Gaïes; Sameh Trabelsi; Emna Kooli; Nadia Kourda; Jaouida Abdelmoula; Mohamed Lakhal; Anis Klouz
Journal:  Hepatol Int       Date:  2011-03-23       Impact factor: 6.047

7.  The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

8.  Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function.

Authors:  J E McDonagh; V V Nathan; I C Bonavia; G R Moyle; A R Tanner
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

9.  Effect of phenobarbital on serum and biliary parameters in a patient with Crigler-Najjar syndrome, type II and acquired cholestasis.

Authors:  B W Trotman; L Shaw; J Roy-Chowdhury; P F Malet; E F Rosato
Journal:  Dig Dis Sci       Date:  1983-08       Impact factor: 3.199

10.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.